GET DAILY SIGNALSA Closer Look at Intelligent Bio Solutions Inc. (INBS) and Its Non-Invasive Testing Platform
Key Takeaways
- Intelligent Bio Solutions Inc. (INBS) is a medical technology company that develops rapid, non-invasive drug screening and testing solutions.
- Its flagship product, the Intelligent Fingerprinting Drug Screening System, uses fingerprint sweat analysis to detect drugs of abuse in about ten minutes.
- The company operates a "razor-and-razorblade" business model, selling portable readers plus recurring, higher-margin cartridge consumables.
- Headquartered in New York, INBS generates most of its revenue outside the United States, with the United Kingdom as its largest market, while pursuing U.S. regulatory clearance.
- As an early-stage medical device business, INBS is growing revenue but has not yet reached profitability.
Company Background
Intelligent Bio Solutions Inc. (INBS) focuses on healthcare technology, particularly its non-invasive drug testing platform. Rather than using urine or saliva samples, the system examines fingerprint sweat to identify recent drug use. The approach is positioned as quicker, cleaner, and less intrusive, which appeals to employers in safety-sensitive fields. From what I see, investors track INBS for its recurring-revenue structure, international sales progress, and efforts to enter the sizable U.S. drug screening market.
Business Model and Operations
The company was founded in 2016 and is based in New York, with manufacturing and operations also in the United Kingdom and Australia. It was previously called GBS Inc. before adopting its current name in October 2022 and trades on Nasdaq. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The main product is the Intelligent Fingerprinting Drug Screening System, which includes a handheld reader and disposable cartridges. A finger press on the cartridge collects the sample, with results ready in under ten minutes. It detects substances such as opiates, cocaine, methamphetamine, cannabis, benzodiazepines, methadone, and buprenorphine. INBS additionally offers the SMARTOX SmarTest Patch, a wearable that gathers sweat over multiple days for extended detection windows.
INBS follows a classic razor-and-razorblade model: hardware sales create an installed base, while cartridges drive recurring revenue with better margins. Cartridges now represent a larger portion of sales and support gross margin expansion. Customers are concentrated in construction, manufacturing, transport, mining, drug treatment, and forensic areas, with activity in more than two dozen countries.
Investor Considerations
Attention centers on the differentiated technology, recurring revenue potential, and addressable market. Fingerprint-based analysis stands apart from traditional methods by reducing privacy issues and tampering risks while supporting workplace safety. A major longer-term factor is the pending FDA 510(k) submission for U.S. clearance, which would open access to one of the world’s largest drug screening markets. Until then, revenue comes primarily from international operations, especially the United Kingdom. Management highlights growth in reader installations and customer accounts as the base for future consumable sales, supported by manufacturing partnerships aimed at cost reduction and margin gains.
Risks to Monitor
INBS remains an early-stage company with modest revenue that has not reached profitability. Ongoing investments in regulatory work and expansion mean continued net losses, which could lead to additional financing and potential dilution. Success in the U.S. hinges on FDA clearance, an uncertain process with no guaranteed outcome. Growth currently depends on international markets and a focused product line, creating exposure to competition from established testing providers. Other factors include currency fluctuations from global operations, possible customer concentration in key sectors, and typical risks for small-cap medical device firms such as limited history and economic sensitivity. Investors need to balance growth prospects against ongoing cash requirements and operating losses.
Using AI Tools in Research
When evaluating opportunities like this one, I find it helpful to run quick comparisons across the broader market. Tickeron’s AI-powered platforms can surface relevant ideas based on technicals, fundamentals, and patterns, which supports a more efficient review process without replacing individual due diligence.
Conclusion
Intelligent Bio Solutions holds a distinct position in medical technology through its fingerprint-based drug screening system and cartridge-focused recurring revenue model. Its foundation rests on proprietary technology and established international adoption, while the path to U.S. clearance offers a notable expansion opportunity. For investors, INBS provides exposure to workplace drug testing and safety screening, set against the typical risks of an early-stage company working toward profitability and wider market entry.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INBS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for INBS turned positive on October 16, 2026. Looking at past instances where INBS's MACD turned positive, the stock continued to rise in 35 of 38 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on INBS as a result. In 65 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
INBS moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for INBS crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +30.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where INBS advanced for three days, in 153 of 182 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 42 of 56 cases where INBS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Bearish Trend Analysis
The 10-day RSI Indicator for INBS moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 17 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INBS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
INBS broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.186) is normal, around the industry mean (4.142). P/E Ratio (-0.233) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.688) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. INBS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement